Summary
Hemab Therapeutics Holdings, Inc. has set the price for its initial public offering at $18.00 per share. The company is offering 16,750,000 shares of common stock and has given underwriters a 30-day option to acquire up to an additional 2,512,500 shares at the same price.
Deal specifics and timing
The public offering is expected to generate approximately $301.5 million in gross proceeds before underwriting discounts and commissions, not accounting for any exercise of the additional share option. Shares are slated to begin trading on the Nasdaq Global Select Market under the ticker symbol "COAG" on May 1, 2026. The offering is expected to close on or about May 4, 2026.
The Securities and Exchange Commission declared the registration statement for the securities effective on April 30, 2026. All shares in the offering are being sold by the company.
Underwriting
Goldman Sachs & Co. LLC, Jefferies and Evercore ISI are serving as joint book-running managers for the transaction. Wedbush PacGrow is participating as lead manager. The underwriters hold a 30-day option to buy the additional shares at the IPO price.
Business and pipeline
Hemab is a clinical-stage biotechnology company focused on treatments for blood coagulation disorders. Its pipeline includes sutacimig, identified as HMB-001, a bispecific antibody in clinical development for Glanzmann thrombasthenia and Factor VII deficiency. The company also lists HMB-002, a monovalent antibody candidate for the treatment of Von Willebrand Disease.
Context and market impact
The transaction represents a capital-raising effort by a clinical-stage developer in the biotechnology and healthcare sectors, with proceeds intended to come from the company share sale. Trading commencement on Nasdaq and the stated closing timeline are key operational milestones that market participants will watch in the coming days.
Notes
All factual details above are based on the company statement and the registration statement declared effective by the SEC on April 30, 2026.